Compare MFA & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MFA | MDXG |
|---|---|---|
| Founded | 1997 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 976.0M | 1.0B |
| IPO Year | N/A | N/A |
| Metric | MFA | MDXG |
|---|---|---|
| Price | $9.57 | $6.35 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 2 |
| Target Price | $10.96 | ★ $11.00 |
| AVG Volume (30 Days) | ★ 1.3M | 823.4K |
| Earning Date | 02-18-2026 | 02-25-2026 |
| Dividend Yield | ★ 15.29% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.86 | 0.27 |
| Revenue | $279,011,000.00 | ★ $393,442,000.00 |
| Revenue This Year | N/A | $19.13 |
| Revenue Next Year | $3.18 | $2.11 |
| P/E Ratio | ★ $10.96 | $23.85 |
| Revenue Growth | N/A | ★ 14.77 |
| 52 Week Low | $7.85 | $5.79 |
| 52 Week High | $11.08 | $9.36 |
| Indicator | MFA | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 51.62 | 34.88 |
| Support Level | $9.32 | $6.25 |
| Resistance Level | $9.52 | $6.50 |
| Average True Range (ATR) | 0.17 | 0.21 |
| MACD | -0.03 | -0.07 |
| Stochastic Oscillator | 50.40 | 7.95 |
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets and Lima One.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.